Availability of Inhaled Insulin Promotes Greater Perceived Acceptance of Insulin Therapy in Patients With Type 2 Diabetes

Freemantle, Nick; Blonde, Lawrence; Duhot, Didier; Hompesch, Marcus; Eggertsen, Robert; Hobbs, FD Richard; Martínez, L.; Ross, Stuart A.; Bolinder, Björn; Stridde, E.

doi:10.2337/diacare.28.2.427

Cited by 102 publications

(57 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although not examined in the present study, several trials assessing patients' treatment preferences have shown preferences for EXU over SC insulin (28,29). Taken together with the demonstrated long-term efficacy and safety data obtained in the present study, these patient preference results suggest that EXU may increase the acceptance of insulin therapy in type 1 diabetic patients.…”

Section: ])supporting

confidence: 62%

Two-Year Safety and Efficacy of Inhaled Human Insulin (Exubera) in Adult Patients With Type 1 Diabetes

et al. 2007

View full text Add to dashboard Cite

OBJECTIVE -The purpose of this study was to evaluate the long-term (2-year) safety and efficacy of inhaled human insulin (Exubera [insulin human (rDNA origin)] inhalation powder) (EXU) in adult patients with type 1 diabetes. , indicating that the significant difference between the treatment groups in FEV 1 developed during the first 3 months and was not progressive thereafter. Adverse event profiles were similar except for a higher incidence of cough (usually mild and unproductive) in patients receiving EXU (37.6 vs. 13.1%) that decreased to 1.3% by month 24. Glycemic control was sustained in both groups (adjusted mean treatment difference in change from baseline A1C at month 24 0.25 Ϯ 0.07% [0.13-0.37]). Although the overall hypoglycemic events were comparable between groups (4.0 vs. 3.8 events/subject-month), the incidence of severe hypoglycemic events was lower with EXU than with SC insulin (2.8 vs. 4.1 events/100 subject-months, risk ratio 0. RESEARCH DESIGN AND METHODS

show abstract

Section: ])supporting

confidence: 62%

Two-Year Safety and Efficacy of Inhaled Human Insulin (Exubera) in Adult Patients With Type 1 Diabetes

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Inhaled insulin represents a promising and practical alternative way of insulin delivery [5], with demonstrated proof of principle for effective pulmonary delivery in clinical trials involving patients with diabetes [4]. Multiple studies have shown that such patients prefer inhaled to injected regimens [1,[6][7][8], which may lead to greater patient acceptance of daily insulin administration and improved therapeutic outcomes.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes

et al. 2006

View full text Add to dashboard Cite

Aims/hypothesis: The efficacy and safety of human insulin inhalation powder (HIIP) plus insulin glargine were compared to subcutaneously injected insulin (SC insulin) plus insulin glargine in patients with type 1 diabetes. Methods: This was a randomised, open-label crossover study in which one group of patients received preprandial HIIP plus insulin glargine for 12 weeks, followed by the same duration with preprandial SC insulin (lispro or regular) plus insulin glargine. Another group of patients received the reverse treatment sequence. The trial was designed as a non-inferiority comparison of the two treatments for effect on HbA 1c ; blood glucose levels were also monitored. Safety assessments included adverse event reporting and hypoglycaemic events. Results: HbA 1c at endpoint was 7.95±0.12% for the HIIP treatment and 8.06±0.12% for the SC insulin treatment; mean changes from baseline to endpoint were −0.08 and 0.00%, respectively, (p=NS). The upper limit of the 95% CI of mean difference in HbA 1c between the two treatments was 0.02%, indicating that HIIP was not inferior relative to SC insulin, as measured against the pre-defined margin of 0.3%. Fasting blood glucose was significantly lower for HIIP treatment (8.09±0.33 mmol/l; n=117) than for SC insulin treatment (9.05±0.33 mmol/l; n=111) (p=0.01). Safety profiles were comparable between the two treatments. The rate of any hypoglycaemia (least-squares mean adjusted for 30 days±SE) was 8.9±0.7 and 8.2±0.8 for HIIP and SC insulin treatments, respectively, (p=0.29). The rate of nocturnal hypoglycaemia was greater for HIIP (4.2±0.4) than for SC insulin (2.7±0.4; p<0.001). Conclusions/interpretation: HIIP was similar in efficacy to SC insulin for glycaemic control in type 1 diabetes mellitus. The two treatments had comparable safety profiles.

show abstract

“…8,9 Patients also expressed greater preference for inhaled insulin and were more likely to accept insulin therapy when this option was available. 16,17 Inhaled insulin is likely to be more expensive than injected insulin (at least initially). In addition, there will be costs associated with training and monitoring for side effects.…”

Section: Efficacy and Safety Of Inhaled Insulinmentioning

confidence: 99%

Needle‐free insulin: from dreams to reality

Bellary

Barnett

2006

Pract Diab Int

View full text Add to dashboard Cite

Availability of Inhaled Insulin Promotes Greater Perceived Acceptance of Insulin Therapy in Patients With Type 2 Diabetes

Cited by 102 publications

References 5 publications

Two-Year Safety and Efficacy of Inhaled Human Insulin (Exubera) in Adult Patients With Type 1 Diabetes

Two-Year Safety and Efficacy of Inhaled Human Insulin (Exubera) in Adult Patients With Type 1 Diabetes

Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes

Needle‐free insulin: from dreams to reality

Contact Info

Product

Resources

About